X0306 4 2014-07-29 0001437786 Immune Design Corp. IMDZ 0001399763 Alta Partners VIII, L.P. ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 0001399894 Alta Partners Management VIII, LLC ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 0001198330 NOHRA GUY P ONE EMBACADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 0001198325 JANNEY DANIEL ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 0001198321 CHAMPSI FARAH ONE EMBACADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 Common Stock 2014-07-29 4 C 0 733943 A 733943 D Common Stock 2014-07-29 4 C 0 531843 A 1265786 D Common Stock 2014-07-29 4 C 0 611620 A 1877406 D Common Stock 2014-07-29 4 C 0 305810 A 2183216 D Common Stock 2014-07-29 4 P 0 299559 12.00 A 2482775 D Series A Preferred Stock 2014-07-29 4 C 0 733943 0 D Common Stock 733943 0 D Series B Preferred Stock 2014-07-29 4 C 0 531843 0 D Common Stock 531843 0 D Series C Preferred Stock 2014-07-29 4 C 0 611620 0 D Common Stock 611620 0 D Series C Preferred Stock Warrant (right to buy) 8.175 2014-07-29 4 X 0 305810 0 D 2013-10-16 Series C Preferred Stock 305810 0 D Series C Preferred Stock 2014-07-29 4 X 0 305810 0 A Common Stock 305810 305810 D Series C Preferred Stock 2014-07-29 4 C 0 305810 0 D Common Stock 305810 0 D Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. The securities are held of record by Alta Partners VIII, L.P. ("APVIII"). Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. Guy Nohra, Daniel Janney and Farah Champsi are managing directors of APMVIII and exercise shared voting and investment power with respect to the shares owned by APVIII. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. The warrants were set to expire on the earlier of: (a) October 15, 2015, (b) the latter of (i) 30 days after delivery to the warrant holder of the interim study report of a specified clinical trial by the Issuer or (ii) 30 days after notice to the warrant holder of the commencement of patient recruitment for specified studies or trials by the Issuer, (c) a liquidation event of the Issuer or (d) the closing of the Issuer's initial public offering. /s/ Laura A. Berezin, Attorney-in-Fact 2014-07-31